Clinical Trial Update: A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety, tolerability, and immunogenic response of MCV4, Tdap, and Bivalent rLP2086 vaccine co-administered in children aged 10…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Bivalent rLP2086 (rLP2086 (N. meningitidis outer membrane protein complex))
• MCV4 (MenACWY vaccine)
• Tdap (Tetanus, diphtheria, and acellular pertussis vaccine)

Snippet

Sponsor: Pfizer | Conditions: Vaccines, Meningococcal Vaccines | Phase 2 | Status: COMPLETED | Results posted: 2015-05-25